Multi-omics in Crohn's disease: New insights from inside
Related Experiment Video
Updated: Jul 27, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Chenlu Mu1, Qianjing Zhao1, Qing Zhao1
1Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China.
Insights
Multi-omics analysis offers a comprehensive approach to understanding Crohn
Area of Science:
- Gastroenterology and Immunology
- Genomics, Epigenomics, Microbiomics, Metabolomics, and Proteomics
Background:
- Crohn's disease (CD), a type of inflammatory bowel disease (IBD), presents complex symptoms and lacks a definitive cure despite rising global incidence.
- Current understanding of CD pathogenesis is limited by the inability of single omics technologies to holistically address disease heterogeneity.
Purpose of the Study:
- To review and synthesize the distinct omics features and applications relevant to Crohn's disease research.
- To discuss the current advancements and limitations of multi-omics approaches in exploring CD.
- To highlight the potential of integrated omics for developing targeted, personalized therapeutics for CD.
Main Methods:
- Review of high-throughput sequencing technologies and integrated omics analyses, including genomics, epigenomics, microbiome, metabolomics, and proteomics.
- Analysis of how different omics data types contribute to understanding CD pathogenesis, biomarkers, and host-microbe interactions.
- Emphasis on the integration of multiple omics datasets for a comprehensive view of CD.
Main Results:
- Host genomics and epigenomics reveal hereditary factors in CD susceptibility.
- Microbiome and metabolomics studies elucidate host-microbe interactions in CD patients.
- Proteomics shows promise for identifying CD biomarkers.
Conclusions:
- Single omics approaches are insufficient for fully connecting CD mechanisms with pathological heterogeneity.
- Multi-omics analysis, by integrating diverse data, provides a powerful tool for in-depth CD exploration.
- This integrated approach offers new hope for advancing targeted and individualized therapeutic strategies for Crohn's disease.
Abstract:
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with complex clinical manifestations such as chronic diarrhea, weight loss and hematochezia. Despite the increasing incidence worldwide, cure of CD remains extremely difficult. The rapid development of high-throughput sequencing technology with integrated-omics analyses in recent years has provided a new means for exploring the pathogenesis, mining the biomarkers and designing targeted personalized therapeutics of CD. Host genomics and epigenomics unveil heredity-related mechanisms of susceptible individuals, while microbiome and metabolomics map host-microbe interactions in CD patients. Proteomics shows great potential in searching for promising biomarkers. Nonetheless, single omics technology cannot holistically connect the mechanisms with heterogeneity of pathological behavior in CD. The rise of multi-omics analysis integrates genetic/epigenetic profiles with protein/microbial metabolite functionality, providing new hope for comprehensive and in-depth exploration of CD. Herein, we emphasized the different omics features and applications of CD and discussed the current research and limitations of multi-omics in CD. This review will update and deepen our understanding of CD from integration of broad omics spectra and will provide new evidence for targeted individualized therapeutics.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Genomics
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

